Article
Health Care Sciences & Services
Andreea Teodorescu, Petru Ifteni, Ana Dragan, Marius Alexandru Moga, Ana Aliana Miron, Lorena Dima
Summary: The postpartum period can lead to psychiatric complications such as postpartum psychoses and post-natal depressions. Postpartum psychoses typically occur within 4 weeks after childbirth with symptoms like emotional lability and delusional beliefs, requiring hospitalization. Treatment options include first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs).
RISK MANAGEMENT AND HEALTHCARE POLICY
(2021)
Article
Clinical Neurology
Shimeng Dong, Johannes Schneider-Thoma, Irene Bighelli, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Kristina Schestag, Myrto Samara, Stefan Leucht
Summary: In this network meta-analysis, the efficacy and adverse events of different antipsychotics in treatment-resistant schizophrenia were examined. The results showed that clozapine and olanzapine were more effective in relieving symptoms compared to other drugs. Clozapine remains the gold standard for patients with treatment-resistant schizophrenia, while olanzapine can be considered as an alternative option.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2023)
Article
Psychiatry
Yuta Kawakita, Masahiro Takeshima, Tomonari Komatsu, Aya Imanishi, Dai Fujiwara, Yu Itoh, Kazuo Mishima
Summary: This study retrospectively compared the incidence of appendicitis in patients with schizophrenia with and without a history of clozapine exposure, finding a relationship between clozapine exposure and appendicitis onset.
Article
Pharmacology & Pharmacy
Izabela Fulone, Marcus Tolentino Silva, Luciane Cruz Lopes
Summary: The study found that in Brazil, factors such as being female, age over 70, residing in the northeast region, and using certain types of antipsychotic medications were associated with an increased risk of switching between second-generation antipsychotics (SGAs). Risperidone was identified as the antipsychotic associated with the highest risk of switching, while clozapine had the lowest risk compared to other SGAs.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Psychology, Clinical
Amir Sariaslan, Stefan Leucht, Johan Zetterqvist, Paul Lichtenstein, Seena Fazel
Summary: In individuals with psychiatric disorders, the use of specific antipsychotic medications such as clozapine, olanzapine, and risperidone is associated with lower risks of arrests and convictions for drug-related and violent crimes compared to other antipsychotics. Long-acting injectables, particularly risperidone, also show lower risks of these criminal outcomes.
PSYCHOLOGICAL MEDICINE
(2022)
Article
Psychiatry
Markku Laehteenvuo, Jurjen J. Luykx, Heidi Taipale, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Albert Batalla, Jari Tiihonen
Summary: This study compared the effects of different antipsychotic medications on the risk of developing substance use disorder (SUD) and hospital admissions in patients with schizophrenia. The results showed that clozapine and antipsychotic polytherapy were most strongly associated with a reduced risk of developing SUD and lower relapse rates.
BRITISH JOURNAL OF PSYCHIATRY
(2022)
Article
Psychiatry
Satoshi Okazaki, Shuken Boku, Ikuo Otsuka, Tadasu Horai, Atsushi Kimura, Naofumi Shimmyo, Naruhisa Yamaki, Akitoyo Hishimoto
Summary: The study demonstrates that antipsychotics such as clozapine increase MIF expression in astrocytes through the acetylation of H3K27, which may play a potential role in the action mechanisms of antipsychotic drugs for schizophrenia patients.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Lena Platanic Arizanovic, Nikola Gligorijevic, Ilija Cvijetic, Aleksandar Mijatovic, Maja Krstic Ristivojevic, Simeon Minic, Aleksandra Nikolic Kokic, Cedo Miljevic, Milan Nikolic
Summary: This study investigated the interaction between antipsychotic drugs and human hemoglobin, and found that the interaction is static and mediated through hydrophobic forces. The association constants were of moderate strength, with clozapine having the highest binding constant. Clozapine showed positive effects on hemoglobin, while bound ziprasidone and sertindole had a slightly pro-oxidative effect. Considering the importance of protein-drug interactions in pharmacokinetics and pharmacodynamics, the physiological significance of these findings is briefly discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Psychiatry
Brian J. Miller, Joseph P. McEvoy, William V. McCall
Summary: This meta-analysis found that patients treated with other antipsychotics had a higher risk of insomnia compared to those treated with clozapine. These findings provide important evidence for the anti-suicidal properties of clozapine and its potential role in improving sleep.
SCHIZOPHRENIA RESEARCH
(2023)
Article
Psychiatry
Risha Govind, Daniela Fonseca de Freitas, Megan Pritchard, Richard D. Hayes, James H. MacCabe
Summary: During the COVID-19 pandemic, patients with schizophrenia-spectrum disorders receiving clozapine treatment had a higher risk of COVID-19 infection, although the risk was attenuated after adjusting for certain confounders. These findings provide support for the hypothesis that clozapine treatment is associated with an increased risk of COVID-19 infection, and further research in other populations is needed to confirm this association.
BRITISH JOURNAL OF PSYCHIATRY
(2021)
Article
Psychiatry
Eric Clapham, Johan Reutfors, Marie Linder, Lena Brandt, Johan Sundstrom, Robert Boden
Summary: The risk of cardiac adverse events following the use of clozapine is debated; however, its risk for chemically related antipsychotics olanzapine and quetiapine is unknown. A Swedish study used registers to analyze the risk of perimyocarditis and heart failure in patients receiving these antipsychotics. The study found that clozapine use was associated with a significantly increased short-term risk of perimyocarditis and an increased long-term risk of heart failure. Olanzapine and quetiapine use did not show an increased risk compared to no antipsychotic treatment.
PSYCHIATRY RESEARCH
(2023)
Article
Psychiatry
Mi Yang, Qiwen Li, Chunzhi Wang, Li Li, Min Xu, Fei Yan, Wei Chen, Ying Wan
Summary: Hospital-acquired pneumonia (HAP) in hospitalized middle-aged and elderly patients with schizophrenia is associated with older age, male gender, and longer hospitalization duration. Specific antipsychotic drugs such as quetiapine, clozapine, and olanzapine, as well as combination with aceglutamide, are risk factors for HAP infection. Minimizing the types and dosages of antipsychotic drugs while monitoring mental symptoms is important in preventing HAP in this population.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Psychiatry
Edouard-Jules Laforgue, Marion Istvan, Anicet Chaslerie, Pascal Artarit, Genevieve Vallot, Pascale Jolliet, Marie Grall-Bronnec, Caroline Victorri-Vigneau
Summary: This study analyzed the different sequences of antipsychotic treatments before initiating clozapine and categorized them into clusters. The results showed that, on average, patients attempted 3.2 different antipsychotics in the 36 months prior to starting clozapine. The different treatment trajectories were associated with individual characteristics and treatment differences.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
(2023)
Article
Medicine, Research & Experimental
Alessandra Manca, Jacopo Mula, Alice Palermiti, Flavio Vischia, David De Cori, Sara Venturello, Guido Emanuelli, Domenico Maiese, Miriam Antonucci, Amedeo De Nicolo, Elisa Delia De Vivo, Jessica Cusato, Antonio D'Avolio
Summary: Schizophrenia affects 24 million people worldwide, and although clozapine is the most effective antipsychotic drug, its use is limited due to adverse effects. Therapeutic drug monitoring can help reduce clozapine toxicity, but few studies have investigated the role of vitamin D in affecting clozapine exposure. Analysis of a TDM database showed that clozapine toxic plasma levels were more common in winter and there was a correlation between vitamin D and clozapine plasma levels. Further studies are needed to clarify these aspects.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Mariana Alves Soares, Andre Luiz A. Costa, Natalia L. C. Silva, Aline Franca Martins, Daiane Oliveira Matias, Olga M. O. Araujo, RicardoTadeu Lopes, Christina Maeda Takiya, Ana Luisa P. Miranda, Leandro Miranda-Alves, Jorge L. M. Tributino
Summary: This study evaluated the effects of clozapine and olanzapine on periodontitis using an animal model. The results suggest that these drugs may increase the risk of periodontal disease, independent of systemic metabolic alterations.
JOURNAL OF PERIODONTAL RESEARCH
(2023)
Article
Psychology, Clinical
Alex G. Segura, Gisela Mezquida, Albert Martinez-Pinteno, Patricia Gasso, Natalia Rodriguez, Lucia Moreno-Izco, Silvia Amoretti, Miquel Bioque, Antonio Lobo, Ana Gonzalez-Pinto, Alicia Garcia-Alcon, Alexandra Roldan-Bejarano, Eduard Vieta, Elena de la Serna, Alba Toll, Manuel J. Cuesta, Sergi Mas, Miquel Bernardo
Summary: Early intervention is crucial for preventing the progression of psychotic disorders. This study found that genetic susceptibility related to cognitive performance is associated with an increased risk of first-episode psychosis (FEP) and its clinical and cognitive progression. Additionally, genetic susceptibility for depression is associated with a worsening trajectory of executive function and general cognitive status.
PSYCHOLOGICAL MEDICINE
(2023)
Review
Clinical Neurology
Giovanna Fico, Ulker Isayeva, Michele De Prisco, Vincenzo Oliva, Brisa Sole, Laura Montejo, Iria Grande, Nestor Arbelo, Marta Gomez-Ramiro, Luis Pintor, Bernardo Carpiniello, Mirko Manchia, Eduard Vieta, Andrea Murru
Summary: This systematic review and meta-analysis investigates the repurposing of psychotropic drugs in the treatment of COVID-19. The study finds that antidepressants do not significantly affect the risk and mortality of COVID-19, while fluvoxamine may have potential in reducing mortality risk. Antipsychotics may increase the risk of severe COVID-19 and mortality, but their use in psychiatric patients should be evaluated on a case-by-case basis.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Marco Solmi, Giovanni Croatto, Giada Piva, Stella Rosson, Paolo Fusar-Poli, Jose M. Rubio, Andre F. Carvalho, Eduard Vieta, Celso Arango, Nicole R. DeTore, Elizabeth S. Eberlin, Kim T. Mueser, Christoph U. Correll
Summary: Psychosocial interventions play an important role in schizophrenia and early psychosis. However, the literature on this topic is heterogeneous and contradictory. This umbrella review summarizes the findings from multiple meta-analyses comparing the effectiveness of different psychosocial interventions with standard treatment or other active interventions. The results suggest that early intervention services and cognitive behavioral therapy have significant effects on symptom reduction and functional improvement in early psychosis. For schizophrenia patients, cognitive behavioral therapy, psychoeducation, and any family interventions show positive effects on symptom reduction, relapse prevention, and functional improvement.
MOLECULAR PSYCHIATRY
(2023)
Review
Biochemistry & Molecular Biology
Giovanni Croatto, Davy Vancampfort, Alessandro Miola, Miriam Olivola, Jess G. Fiedorowicz, Joseph Firth, Ovidiu Alexinschi, Marcel A. Gaina, Vladimir Makkai, Fernanda Cunha Soares, Leandro Cavaliere, Giorgia Vianello, Brendon Stubbs, Paolo Fusar-Poli, Andre F. Carvalho, Eduard Vieta, Samuele Cortese, Jae Il Shin, Christoph U. Correll, Marco Solmi
Summary: People with mood disorders are at increased risk of comorbid medical diseases. Interventions such as psychological therapies, exercise, and certain medications can improve physical health outcomes in mood disorders, but some medications may have negative effects. It is important to consider evidence from other disorders and individual RCTs when prioritizing effective treatments with beneficial or physically neutral profiles.
MOLECULAR PSYCHIATRY
(2023)
Article
Clinical Neurology
Ana M. Sanchez-Torres, Silvia Amoretti, Monica Enguita-German, Gisela Mezquida, Lucia Moreno-Izco, Rocio Panadero-Gomez, Lide Rementeria, Alba Toll, Roberto Rodriguez-Jimenez, Alexandra Roldan, Edith Pomarol-Clotet, Angela Ibanez, Judith Usall, Fernando Contreras, Eduard Vieta, Jose M. Lopez-Ilundain, Jessica Merchan-Naranjo, Ana Gonzalez-Pinto, Esther Berrocoso, Miguel Bernardo, Manuel J. Cuesta
Summary: This study aimed to investigate the relationship between relapse, cognitive function, and cognitive reserve in schizophrenia patients. The results showed that higher personal cognitive reserve mitigated the negative effects of relapse on attention performance, while higher cognitive reserve (both personal and familial) improved processing speed and visual memory in patients who did not relapse. These findings provide evidence for the protective effect of cognitive reserve over the course of the illness.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Editorial Material
Clinical Neurology
Cristian-Daniel Llach, Eduard Vieta
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Correction
Clinical Neurology
V. Perez, M. Elices, G. Vilagut, E. Vieta, J. Blanch, E. Laborda-Serrano, B. Prat, F. Colom, D. Palao, J. Alonso
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Norma Verdolini, Silvia Alonso-Lana, Pilar Salgado-Pineda, Salvador Sarro, Raymond Salvador, Teresa Maristany, Jose M. Goikolea, Caterina M. Bonnin, Ines Martin, Laura Salo, Ana Romaguera, Elena Rodriguez-Cano, Adriane R. Rosa, Eduard Vieta, Edith Pomarol-Clotet
Summary: This study aimed to assess the brain functional correlates of psychosocial functioning in individuals with bipolar disorder during a working memory task. The results revealed differences in brain activation between bipolar patients and healthy controls, particularly in the medial frontal cortex. In addition, the study found inverse correlations between psychosocial functioning and brain activation in several cortical regions, including the frontal, parietal, and temporo-occipital regions.
PSYCHIATRY RESEARCH
(2023)
Editorial Material
Psychiatry
Eduard Vieta
Article
Neurosciences
Norma Verdolini, Gisela Mezquida, Isabel Valli, Clemente Garcia-Rizo, Manuel Cuesta, Eduard Vieta, Miquel Bioque, Antonio Lobo, Ana Gonzalez-Pinto, Laura Pina-Camacho, Iluminada Corripio, Marina Garriga, Inmaculada Baeza, Laura Martinez-Sadurni, Byron Bitanihirwe, Mary Cannon, Miquel Bernardo
Summary: This study examined the relationship between obstetric complications (OCs) and clinical phenotypes in patients with a first episode of psychosis (FEP). The results showed that OCs were associated with more severe psychopathology, highlighting the importance of OCs in understanding the heterogeneity of clinical presentation in psychosis.
ACTA NEUROPSYCHIATRICA
(2023)
Review
Psychiatry
Natalia E. Fares-Otero, Michele De Prisco, Vincenzo Oliva, Joaquim Radua, Sarah L. Halligan, Eduard Vieta, Anabel Martinez-Aran
Summary: This study conducted a systematic review and meta-analysis to examine the associations between childhood maltreatment and social functioning and social cognition in adults with affective disorders. The findings showed that childhood maltreatment was associated with lower social functioning and aggressive behavior, but not with vocational functioning. There was no evidence of associations between maltreatment and social cognition domains. Moderation analyses did not find consistent moderators, but attachment style and mediators such as sensory patterns, anxiety, and depressive symptoms were identified.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Article
Psychology, Clinical
Adrian I. Campos, Laura S. Van Velzen, Dick J. Veltman, Elena Pozzi, Sonia Ambrogi, Elizabeth D. Ballard, Nerisa Banaj, Zeynep Basgoeze, Sophie Bellow, Francesco Benedetti, Irene Bollettini, Katharina Brosch, Erick J. Canales-Rodriguez, Emily K. Clarke-Rubright, Lejla Colic, Colm G. Connolly, Philippe Courtet, Kathryn R. Cullen, Udo Dannlowski, Maria R. Dauvermann, Christopher G. Davey, Jeremy Deverdun, Katharina Dohm, Tracy Erwin-Grabner, Roberto Goya-Maldonado, Negar Fani, Lydia Fortea, Paola Fuentes-Claramonte, Ali Saffet Gonul, Ian H. Gotlib, Dominik Grotegerd, Mathew A. Harris, Ben J. Harrison, Courtney C. Haswell, Emma L. Hawkins, Dawson Hill, Yoshiyuki Hirano, Tiffany C. Ho, Fabrice Jollant, Tanja Jovanovic, Tilo Kircher, Bonnie Klimes-Dougan, Emmanuelle le Bars, Christine Lochner, Andrew M. McIntosh, Susanne Meinert, Yara Mekawi, Elisa Melloni, Philip Mitchell, Rajendra A. Morey, Akiko Nakagawa, Igor Nenadic, Emilie Olie, Fabricio Pereira, Rachel D. Phillips, Fabrizio Piras, Sara Poletti, Edith Pomarol-Clotet, Joaquim Radua, Kerry J. Ressler, Gloria Roberts, Elena Rodriguez-Cano, Matthew D. Sacchet, Raymond Salvador, Anca-Larisa Sandu, Eiji Shimizu, Aditya Singh, Gianfranco Spalletta, J. Douglas Steele, Dan J. Stein, Frederike Stein, Jennifer S. Stevens, Giana I. Teresi, Aslihan Uyar-Demir, Nic J. van der Wee, Steven J. van der Werff, Sanne J. H. van Rooij, Daniela Vecchio, Norma Verdolini, Eduard Vieta, Gordon D. Waiter, Heather Whalley, Sarah L. Whittle, Tony T. Yang, Carlos A. Zarate Jr, Paul M. Thompson, Neda Jahanshad, Anne-Laura van Harmelen, Hilary P. Blumberg, Lianne Schmaal, Miguel E. Renteria
Summary: A major limitation of current suicide research is the lack of power to identify robust correlates of suicidal thoughts or behavior. Variation in suicide risk assessment instruments used across cohorts may represent a limitation to pooling data in international consortia. Our findings suggest that multi-item instruments provide valuable information on different aspects of suicidal thoughts or behavior but share a modest core factor with single suicidal ideation items. Retrospective, multisite collaborations including distinct instruments should be feasible provided they harmonize across instruments or focus on specific constructs of suicidality.
Article
Psychiatry
Diego Hidalgo-Mazzei, Tim Mantingh, Xavier Perez de Mendiola, Ludovic Samalin, Juan Undurraga, Sergio Strejilevich, Emanuel Severus, Michael Bauer, Ana Gonzalez-Pinto, Willem A. Nolen, Allan H. Young, Eduard Vieta
Summary: A global survey conducted by the ISBD Task Force on the Role of Lithium in Bipolar Disorders revealed potential factors contributing to the decline in lithium prescriptions in the past two decades. The survey received 886 responses from 43 different countries, showing that lithium remains the preferred treatment option for bipolar disorder maintenance (59%), but negative beliefs, acute side effects, tolerability problems, and intoxication risk are reasons for not choosing lithium.
INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS
(2023)
Article
Neurosciences
Vivian Accardo, Stefano Barlati, Anna Ceraso, Gabriele Nibbio, Eduard Vieta, Antonio Vita
Summary: This study aims to evaluate the effectiveness of functional remediation (FR) in improving neurocognitive dysfunctions in patients with bipolar disorder (BD) compared to treatment as usual (TAU). The Brief Assessment of Cognition in Affective Disorders (BAC-A) and the Functioning Assessment Short Test (FAST) will be used to measure neurocognitive damage and overall psychosocial functioning, respectively. The expected outcome is that patients who undergo FR intervention will show improved cognitive abilities and psychosocial outcomes compared to the TAU group.
Review
Biochemistry & Molecular Biology
Sourav Khanra, Preethi Reddy, Anna Gimenez-Palomo, Chun Hui J. Park, Bruna Panizzutti, Madeleine McCallum, Shyam Sundar Arumugham, Shreekantiah Umesh, Monojit Debnath, Basudeb Das, Ganesan Venkatasubramanian, Melanie Ashton, Alyna Turner, Olivia M. Dean, Ken Walder, Eduard Vieta, Lakshmi N. Yatham, Isabella Pacchiarotti, Y. C. Janardhan Reddy, Nishant Goyal, Muralidharan Kesavan, Lluc Colomer, Michael Berk, Jee Hyun Kim
Summary: The core feature of bipolar disorder is pathological disturbances in mood, along with disrupted thinking and behavior. Due to its complex and heterogeneous etiology, a range of genetic and environmental factors are involved. This complexity and poorly understood neurobiology make it challenging to develop drugs, resulting in limited treatment options, especially for bipolar depression. Therefore, novel approaches are needed, such as investigating the potential of trimetazidine as a treatment option for bipolar depression.
MOLECULAR PSYCHIATRY
(2023)
